Abstract
In Germany more than 80% of newly diagnosed children with acute myelogenous leukemia are treated within the cooperative Berlin-Frankfurt-Münster (BFM) studies. Complete remissions (CR) of 80% are achieved with these protocols but one-third of patients relapse within the first 3 years [1]. There are only a few studies on the treatment of relapsed childhood AML; these aim at evaluating new antileukemic drugs for frontline therapy. Most of the studies enrolled either patients with relapsed AML or patients with leukemia refractory to frontline treatment. With various therapeutic regimens complete remission rates of 45%–49% were achieved [2–5]. Except for patients with allogenic bone marrow transplantation, reports on long-time survival are lacking.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Creutzig U, Ritter J, Schellong G (1990) Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. Blood 75: 1932–1940
Mirro J, Crom WR, Kalwinsky DK, Santane VM, Baker DK, Belt J (1990) Targeted plasma drug concentration: a new therapeutic approach to relapsed nonlymphoblastic leukemia in children. Hematology and Blood Transfusion 32: 82–86
Movassaghi N, Higgins G, Pyesmany A, Baehner R, Chard R, Sather H, Hammond D (1984) Evaluation of Cyclocytidine in reinduction and maintenance therapy of children with acute nonlymphocytic leukemia previously treated with Cytosine Arabinoside: A Report from Children’s Cancer Study Group. Medical and Pediatric Oncology 12: 352–356
Miller LP, Pyesmany AF, Wolff LJ, Rogers PCJ, Siegel SE, Wells RJ, Buckley JD, Hammond GD (1991) Successful reinduction therapy with Amsacrine and Cyclocytidine in acute nonlymphoblastic leukemia in children. Cancer 67: 2235–2240
Hakami N, Look AT, Steuber PC, Krischer J, Castleberry R, Harris R, Ravindranath Y, Yietti TJ (1987) Combined Etoposide and 5-Azacitidine in children and adolescents with refractory or relapsed acute non lymphocytic leukemia: A Pediatric Oncology Group Study. J Clin Oncol 5: 1022–1025
Ritter J, Creutzig U, Henze G, Jürgens H, Bode U, Prindull G, Schellong G (1987) Hochdosiertes ARA-C in Kombination mit Mitoxantron bei der Therapie der AML in Kindesalter. Erste Ergebnisse der AML-Rezidivstudie BFM-85. Onkologie 10: 24–27
Kantarjian HM, Keating MJ, Walters RS, CrCredie KB, Freireich EJ (1988) The characteristics and outcome of patients with late relapse acute myelogenous leukemia. Journal of Clinical Oncology 6(2): 232–238
Hiddemann W, Martin W-R, Sauerland C-M, Heinecke A, Büchner T (1990) Definition of refractoriness against conventional chemotherapy in acute myeloid Leukemia: A proposal based on the results of retreatment by Thioguanine, Cytosine, Arabinoside and Daunorubicin (TAD 9) in 150 patients with relapse after standardized first line Therapy Leukemia 4(3): 184–188
Author information
Authors and Affiliations
Consortia
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Stahnke, K., Creutzig, U., Ritter, J., AML-BFM Study Group. (1994). Second Remission in Relapsed Childhood Acute Myelogenous Leukemia After Pretreatment with the AML-BFM 83 Protocol. In: Büchner, T., Hiddemann, W., Wörmann, B., Schellong, G., Ritter, J. (eds) Acute Leukemias IV. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 36. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78350-0_90
Download citation
DOI: https://doi.org/10.1007/978-3-642-78350-0_90
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-78352-4
Online ISBN: 978-3-642-78350-0
eBook Packages: Springer Book Archive